Acepodia

Acepodia is a clinical stage biotech company dedicated to the development of targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers. Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and γδ T cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable and safe. The Antibody-Conjugated Effector (ACE) cells significantly increases the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly. Our vision is to develop an off-the shelf cell therapy that is potent, safe and broadly applicable across hematologic and solid tumor cancers. Our lead product candidate, ACE1702, is an anti-HER2 antibody-conjugated NK cell therapy entering in Phase I trial at U.S. for the treatment of HER2-expressing solid tumors. The second program, ACE1831, is an anti-CD20-antibody-conjugated γδ T cell therapy being on track for IND filing to the US FDA in the second half of 2021.